FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Managed Healthcare Executive3d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
Medscape1d
Room-temperature Storage of Medications Labeled for Refrigeration
vial Novolog Mix 70/30 vial (Novo Nordisk) 28 days Prescribing information Lente human insulin (rDNA origin) zinc suspension Humulin L (Lilly) 28 days Prescribing information Insulin lispro (rDNA ...
Interesting Engineering on MSN4d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
U.S. News & World Report3d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog is a rapid-acting human insulin analog and the first rapid-acting ... Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.
Sierra Sun Times5d
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...